Given the role of the pro-inflammatory pathway Fas/FasL in the expression of inflammatory genes in smooth muscle cells [21], [22], we hypothesized that the vascular effects of MetS MPs may be mediated by the interaction of FasL, harbored by MetS MPs, and Fas receptor expressed by smooth muscle cells from the vascular wall [41]. The gene discussed is FAS; the disease is metabolic syndrome.